인비비드 (IVVD) 주가

인비비드(IVVD)는 NASDAQ에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $0.75 (+0.90%), 시가총액 $0.36B, 52주 최저~최고 $0.52 ~ $2.88.

Invivyd, Inc., together with its subsidiaries, engages in the research, development, commercialization, and sale of antibody therapies for the prevention and treatment of viral infectious diseases in the United States. The company offers Pemivibart, a half-life extended investigational monoclonal antibody for the pre-exposure prophylaxis prevention of COVID-19 in adults and adolescents through injection under the PEMGARDA brand. It also develops VYD2311, a monoclonal antibody, which is in Phase III clinical trial for the prevention and treatment of SARS-CoV-2 virus; and VBY329, a monoclonal antibody, which is in pre-clinical trial stage for the prevention and treatment of respiratory syncyt

핵심 지표

• 현재가: $0.75 (+0.90%)
• 시가총액: $0.36B
• 52주 최저~최고: $0.52 ~ $2.88
• 섹터: Healthcare
• 산업: Biotechnology
• 거래소: NASDAQ

인비비드의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackAll Trade에서 실시간으로 확인할 수 있습니다.

인비비드 재무 요약

애널리스트 전망

• 투자의견 컨센서스: 4

핵심 재무비율 · 수익성 · 성장성

• PBR (주가순자산비율): 1.76
• 순이익률: -1.39%
• 영업이익률: -3.14%

자주 묻는 질문